Zoetis Inc.ZTS
Zoetis Inc. Financial Overview 2021–2025
Zoetis commands the animal health market with a relentless pivot toward pet care, driving companion animal products to a dominant 70% of total revenue in FY2025. This strategic focus on higher-margin dermatology and parasiticides insulates the business from agricultural volatility and fuels highly profitable top-line expansion.
Total revenue grew steadily from $7.78 billion in FY2021 to $9.47 billion in FY2025. Pricing power and favorable product mix pushed net income to $2.67 billion in FY2025, marking an 8% year-over-year increase. The company maintained rigorous operational discipline, improving its cost of sales to just 26.4% of revenue by Q2 2025, aided by the divestiture of its livestock medicated feed additive portfolio. To sustain this momentum, Zoetis funneled $698 million into research and development during FY2025, defending key franchises like Simparica Trio and its novel monoclonal antibody therapies.
Management aggressively returned capital alongside this operational growth, utilizing a massive $6 billion repurchase authorization to shrink the outstanding share count to 0.42 billion. At the close of FY2025, the market valued the company at a $53.5 billion market capitalization, with shares priced at $125.82 and trading at a 20.9x earnings multiple.
Recent Developments (Q3 and Q4 2025)
Zoetis restructured its capital in late 2025 by issuing $2.0 billion in 0.25% convertible senior notes due 2029. The company allocated over $1.5 billion of these proceeds for share repurchases into Q1 2026. Cost of sales improved to 27.6% of revenue over the nine-month period. By year-end, total assets reached $15.47 billion, supported by $4.53 billion in working capital. Management increased the quarterly dividend to $0.53 per share and added a 13th board member during Q4 2025.
Bulls point to 3% operational revenue growth and a year-end cash balance expanding to $2.31 billion. Conversely, bears note that livestock products represent 29% of revenue and consistently lag companion pet segment expansion. Shares traded at 20.9x trailing earnings of $6.02 per share corresponding to the February 11, 2026 reporting date, not today, appearing richly valued relative to single-digit top-line growth.
What to watch: deployment of the remaining $2.4 billion buyback authorization; volume growth for pain therapeutics Librela and Solensia.
Rev
$9.47B
FY2025
NI
$2.67B
FY2025
EPS
$6.03
FY2025
OCF
$2.90B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Zoetis Inc. 8-K Report, Financial Results (Feb 12, 2026)
Zoetis Inc. (ZTS) has filed an 8-K report on February 12, 2026, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2025. The filing also includes the company's financial guidance for the upcoming full year 2026. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial performance metrics and future outlook. While specific figures are not detailed within the 8-K text itself, the furnished press release is the key document for understanding Zoetis' performance in 2025, including revenue, profitability, and key growth drivers. Furthermore, the guidance provided for 2026 will be crucial for assessing the company's strategic direction and potential for continued growth in the animal health sector.
Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 5, 2026)
Zoetis Inc. (ZTS) has filed a Current Report (8-K) on February 5, 2026, primarily announcing its second-quarter 2026 dividend declaration. The company has declared a dividend of $0.53 per share, which is a positive signal to investors regarding the company's financial health and commitment to returning capital to shareholders. This dividend payment is scheduled for June 2, 2026, with a record date of April 20, 2026, providing clear timelines for eligible shareholders.
Zoetis Inc. 8-K Report, Material Agreement (Dec 18, 2025)
Zoetis Inc. has successfully completed a private offering of $2.0 billion in aggregate principal amount of 0.25% Convertible Senior Notes due 2029. The net proceeds, estimated at approximately $1.97 billion after expenses, are earmarked for a significant share repurchase program, with a substantial portion intended for additional repurchases by the first quarter of 2026, supplementing its existing $6 billion repurchase authorization. The company also entered into capped call transactions to mitigate potential dilution from the convertible notes. Additionally, Zoetis obtained a waiver from its lenders under its revolving credit facility to explicitly permit early conversions of these new notes. This strategic financing move, coupled with the share repurchase initiative, signals the company's intent to return capital to shareholders while maintaining financial flexibility. Investors should monitor the execution of the share buyback program and the impact of these new notes on the company's capital structure and future earnings per share.
Zoetis Inc. 8-K Report, Regulation FD Disclosure (Dec 11, 2025)
Zoetis Inc. (ZTS) has announced its first-quarter 2026 dividend, demonstrating a consistent commitment to returning capital to shareholders. The company declared a dividend of $0.53 per share, payable on March 3, 2026, to shareholders of record as of January 20, 2026. This regular dividend payment is a key indicator of the company's financial stability and its confidence in sustained profitability. While this filing is primarily a Regulation FD disclosure regarding the dividend, it underscores Zoetis' ongoing capital allocation strategy. Investors should view this as a positive signal of the company's financial health and its ability to generate consistent cash flows to support shareholder returns. Further analysis of Zoetis' broader financial performance, strategic initiatives, and market position would be necessary for a complete investment assessment.
Zoetis Inc. 8-K Report, Corporate Update (Dec 2, 2025)
Zoetis Inc. (ZTS) has filed a Current Report on Form 8-K to announce an upcoming Innovation Webcast scheduled for December 2, 2025, at 8:30 a.m. ET. The primary purpose of this filing is to provide investors with advance notice of the event and to make available the presentation materials that will be used during the webcast. This webcast is expected to focus on the company's latest innovations, which could include new product pipelines, research and development advancements, or strategic initiatives aimed at driving future growth in the animal health sector. Investors should pay close attention to this webcast as it represents an opportunity to gain insights into Zoetis's forward-looking strategy and its potential impact on future financial performance. The attached presentation, incorporated by reference, will likely detail key areas of innovation, potential market opportunities, and the company's competitive positioning. Understanding these elements is crucial for assessing Zoetis's long-term value proposition and its ability to maintain its leadership in the animal health industry.
View all 8-K filings →